Comparison of the pharmacokinetics of fosinoprilat with enalaprilat and lisinopril in patients with congestive heart failure and chronic renal insufficiency
- 31 January 2000
- journal article
- clinical trial
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 49 (1), 23-31
- https://doi.org/10.1046/j.1365-2125.2000.00103.x
Abstract
Aims To compare the serum pharmacokinetics of fosinoprilat with enalaprilat and lisinopril after 1 and 10 days of dosing with fosinopril, enalapril and lisinopril. Methods Patients with congestive heart failure (CHF, NYHA Class II–IV) and chronic renal insufficiency (creatinine clearance ≤30 ml min−1 ) were randomized to receive fosinopril, enalapril or lisinopril in two parallel-group studies. In the first study 24 patients were treated with 10 mg fosinopril (n=12 patients) or 2.5 mg enalapril (n=12) every morning for 10 consecutive days. In the second study 31 patients were treated with 10 mg fosinopril (n=16 patients) or 5 mg lisinopril (n=15) every morning for 10 consecutive days. Samples of blood were collected for determination of pharmacokinetic parameters. The area under the curve (AUC) between the first and last days of treatment and the accumulation index (AI) were the primary outcome measures. Results All three angiotensin converting enzyme (ACE) inhibitors exhibited a significant increase in AUC between the first and last days of treatment in both studies. The difference between the AI for fosinoprilat (1.41) and enalaprilat (1.96) was statistically significant (95% CI: 1.05, 1.84). Similarly, the difference between the AI for fosinoprilat (1.21) and lisinopril (2.76) was statistically significant (95% CI: 1.85, 2.69). All three ACE inhibitors completely inhibited serum ACE for 24 h. All treatments were well tolerated. Conclusions Fosinoprilat exhibits significantly less accumulation than enalaprilat or lisinopril in patients with CHF and renal insufficiency, most probably because fosinoprilat is eliminated by both the kidney and liver, and increased hepatic elimination can compensate for reduced renal clearance in patients with kidney dysfunction.Keywords
This publication has 25 references indexed in Scilit:
- Fosinopril: An overviewThe American Journal of Cardiology, 1993
- Pharmacokinetic profiles of single and repeat doses of lisinopril and enalapril in congestive heart FailureThe American Journal of Cardiology, 1992
- Comparison of treatment with lisinopril versus enalapril for congestive heart failureThe American Journal of Cardiology, 1992
- Renal function in severe congestive heart failure during treatment with enalapril (the Cooperative North Scandinavian Enalapril Survival Study [CONSENSUS] Trial)The American Journal of Cardiology, 1992
- Comparison of the Steady-State Pharmacokinetics of Fosinopril, Lisinopril and Enalapril in Patients with Chronic Renal InsufficiencyClinical Pharmacokinetics, 1991
- Pharmacokinetics and Antihypertensive Effects of Lisinopril in Hypertensive Patients with Normal and Impaired Renal FunctionJournal of Cardiovascular Pharmacology, 1990
- Clinical Pharmacokinetics in Heart FailureClinical Pharmacokinetics, 1988
- Pharmacokinetics of lisinopril in hypertensive patients with normal and impaired renal functionEuropean Journal of Clinical Pharmacology, 1988
- Pharmacokinetics of lisinopril (MK521) in healthy young and elderly subjects and in elderly patients with cardiac failureJournal of Pharmacy and Pharmacology, 1987
- Pharmacokinetics of Enalapril in Congestive Heart FailureDrugs, 1986